Breaking Down Biologics in Atopic Dermatitis: Choosing the Right Path for Patients - Episode 5
Overview of the Biologics Approved in Atopic Dermatitis
Panelists discuss how the current biologic landscape for atopic dermatitis includes 4 distinct agents with complementary mechanisms: dupilumab targeting IL-4 and IL-13 pathways to broadly inhibit type 2 inflammation, lebrikizumab and tralokinumab both selectively blocking IL-13 to potentially offer similar efficacy with refined targeting, and nemolizumab uniquely addressing the IL-31 “itch cytokine” pathway—each representing different strategic approaches to modulating the complex immunopathology of the disease with specific advantages for different patient phenotypes.
Video content above is prompted by the following:
- We’ll go into more detail in a bit, but can you provide a brief introduction of the biologics currently approved for atopic dermatitis, including how they differ in their mechanisms of action?
- Dupilumab (IL-4/IL-13 inhibitor)
- Lebrikizumab (IL-13 inhibitor)
- Tralokinumab (IL-13 inhibitor)
- Nemolizumab (IL-31 inhibitor)
